Preference evaluation and perceived sensory comparison of fluticasone furoate and mometasone furoate intranasal sprays in allergic rhinitis.
OBJECTIVE
Intranasal corticosteroid sprays (INCSs) are commonly used for therapy of allergic rhinitis (AR). Adherence to regular use of INCSs is influenced by patient perception and preferences of products. The study objective was to compare perceived sensory attributes of fluticasone furoate nasal spray (FFNS) and mometasone furoate nasal spray (MFNS) in AR patients.


METHODS
In a multicenter, randomized, crossover, prospective study, 40 seasonal AR patients were administered both FFNS and MFNS for 2 weeks each in a crossover fashion, for a total of 4 weeks. Patients completed questionnaires for each product regarding perceived sensory attributes at the end of each two-week period of product administration.


RESULTS
FFNS was significantly preferred over MFNS. Significantly, fewer subjects perceived a bitter taste (p=0.01), medication running down their throat (p=0.033), and medication running out of their nose (p=0.002) with FFNS. MFNS was more frequently reported to induce nasal irritation (p=0.012), sneezing (p=0.017), and rhinorrhea (p=0.007) compared to FFNS. Interestingly, these findings were markedly observed in females. Medicine dripping out of the nose and nasal shooting were the most common problems reported for MFNS with a higher proportion of subjects who felt moderate-to-severe discomfort. Overall, 52.5% of patients expressed a preference for FFNS compared with 22.5% for MFNS.


CONCLUSIONS
Several perceived sensory attributes of FFNS were rated significantly superior to MFNS. FFNS may contribute to enhanced treatment outcomes in AR patients due to improved treatment adherence.
Department of Otolaryngology, Utinomi Hospital, Syouzu-gun, Syoudoshima-cho, Henjyoko 44-95, Kagawa 761-4431, Japan; Department of Otolaryngology, Faculty of Medicine, Kagawa University, Kita-gun, Miki-cho, Ikenobe 1750-1, Kagawa 761-0793, Japan.
Masafumi
M
Yonezaki
Department of Otolaryngology, Faculty of Medicine, Kagawa University, Kita-gun, Miki-cho, Ikenobe 1750-1, Kagawa 761-0793, Japan. Electronic address: kakaka@med.kagawa-u.ac.jp.
Kosuke
K
Akiyama
Tanaka ENT Clinic, Tyuou-ku, Shinshigai 7-17, Kumamoto 860-0803, Japan.
Masayuki
M
Karaki
Department of Otolaryngology, Mitoyo General Hospital, Mitoyo-shi, Toyohama-cho, Himehama 708, Kagawa 769-1695, Japan.
Rieko
R
Goto
Department of Otolaryngology, Faculty of Medicine, Kagawa University, Kita-gun, Miki-cho, Ikenobe 1750-1, Kagawa 761-0793, Japan.
Rhyuhei
R
Inamoto
Department of Otolaryngology, Mitoyo General Hospital, Mitoyo-shi, Toyohama-cho, Himehama 708, Kagawa 769-1695, Japan.
Yasushi
Y
Samukawa
Department of Otolaryngology, Ayagawa National Health Insurance Sue Hospital, Ayauta-gun, Ayagawa-cho, Sue 1720-1, Kagawa 761-2103, Japan.
Ryuichi
R
Kobayashi
Kobayashi ENT Clinic, Higashi Kagawa-shi, Sanbonmatsu 1887-1, Kagawa 769-2601, Japan.
Eiji
E
Kobayashi
Department of Otolaryngology, Faculty of Medicine, Kagawa University, Kita-gun, Miki-cho, Ikenobe 1750-1, Kagawa 761-0793, Japan.
Hiroshi
H
Hoshikawa
D000281:Administration, Intranasal; D000328:Adult; D000368:Aged; D000730:Androstadienes / Q000627:therapeutic use*; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D018592:Cross-Over Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000068656:Mometasone Furoate / Q000627:therapeutic use*; D059085:Nasal Sprays; D057240:Patient Preference; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*; D012737:Sex Factors; D012912:Sneezing; D011795:Surveys and Questionnaires; D013649:Taste
D000730:Androstadienes; D018926:Anti-Allergic Agents; D059085:Nasal Sprays; D000068656:Mometasone Furoate; C523187:fluticasone furoate
Allergic rhinitis; Fluticasone furoate nasal spray; Intranasal corticosteroid spray; Mometasone furoate nasal spray; Perceived sensory attribute